Apella Capital LLC Sells 331 Shares of Bristol-Myers Squibb (NYSE:BMY)

Apella Capital LLC decreased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,913 shares of the biopharmaceutical company’s stock after selling 331 shares during the quarter. Apella Capital LLC’s holdings in Bristol-Myers Squibb were worth $334,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of BMY. Laurel Wealth Advisors LLC increased its stake in Bristol-Myers Squibb by 3.3% during the 4th quarter. Laurel Wealth Advisors LLC now owns 7,450 shares of the biopharmaceutical company’s stock valued at $421,000 after purchasing an additional 240 shares in the last quarter. Acropolis Investment Management LLC increased its position in shares of Bristol-Myers Squibb by 39.1% during the fourth quarter. Acropolis Investment Management LLC now owns 34,009 shares of the biopharmaceutical company’s stock worth $1,924,000 after acquiring an additional 9,564 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. lifted its position in Bristol-Myers Squibb by 28.3% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 5,816 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 1,284 shares in the last quarter. Park Avenue Securities LLC boosted its stake in Bristol-Myers Squibb by 32.6% during the 4th quarter. Park Avenue Securities LLC now owns 56,806 shares of the biopharmaceutical company’s stock valued at $3,213,000 after purchasing an additional 13,952 shares during the last quarter. Finally, Kathmere Capital Management LLC grew its holdings in Bristol-Myers Squibb by 33.3% during the fourth quarter. Kathmere Capital Management LLC now owns 10,638 shares of the biopharmaceutical company’s stock worth $602,000 after buying an additional 2,656 shares in the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BMY has been the subject of several recent analyst reports. Morgan Stanley upped their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. Leerink Partners raised shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $55.00 to $73.00 in a research report on Tuesday, November 12th. Leerink Partnrs raised shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 12th. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price target for the company from $63.00 to $70.00 in a research report on Monday, December 16th. Finally, Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $56.27.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock opened at $55.96 on Thursday. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08. The stock has a market capitalization of $113.50 billion, a P/E ratio of -15.59, a PEG ratio of 15.20 and a beta of 0.45. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The firm’s 50 day moving average is $57.44 and its 200 day moving average is $51.76.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The firm had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. During the same period last year, the company earned $2.00 earnings per share. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd will be given a dividend of $0.62 per share. The ex-dividend date of this dividend is Friday, January 3rd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.43%. Bristol-Myers Squibb’s dividend payout ratio is currently -69.08%.

Insider Transactions at Bristol-Myers Squibb

In related news, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares of the company’s stock, valued at approximately $654,091.20. This represents a 5.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Samit Hirawat purchased 1,830 shares of the business’s stock in a transaction on Friday, November 1st. The stock was purchased at an average cost of $54.67 per share, with a total value of $100,046.10. Following the completion of the acquisition, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.